Despite tremendous advancement in the drug delivery, oral route remains the preferred route for drug administration because of low cost therapy and ease of administration leads to higher levels of patient compliance. Metformin HCl, which is an antihyperglycaemic agent widely, used in the management of NIDDM, gives low bioavailability problem due to its site absorption limitations. Although, metformin extended release tablet formulations were well established, but it causes a great fluctuations in plasma drug levels and fail to improve the bioavailability. But microcapsule formulation offer...